Enterprise Software & Data Intelligence / Research Analytics
Strategic Profile
Clarivate is undergoing portfolio optimization with strategic divestitures of transactional revenues while forecasting growth in organic ACV and recurring revenue, with adjusted EBITDA projected to grow alongside a 200 basis point margin expansion. The company is pursuing a sale of its Life Sciences & Healthcare business to reduce debt, improve its balance sheet, and pursue expansion in academia-and-government and intellectual-property categories.
Cyborg Score Rationale
The company guided to 2026 net losses of $124-189 million on revenues of $2.30-2.42 billion, highlighting that profitability remains under pressure even as restructuring and divestitures reduce impairment charges. However, free cash flow is estimated to rise roughly 10% to nearly $400 million, allowing reinvestment and shareholder returns. The margin expansion and debt reduction initiatives suggest path to profitability, offset by near-term losses.
Top Insights
Clarivate completed $100 million accelerated debt repayment in January 2026, fully redeeming senior secured notes due November 2026.
The company realized nearly 2% organic ACV growth and increased recurring organic revenue in 2025.
Clarivate repurchased approximately 56 million ordinary shares for $225 million in 2025, signaling shareholder value focus.
Leveraging proprietary solutions alongside artificial intelligence, the company aims to enhance the value provided to its customers.
Named Competitors
Web of Science — Research performance platform with AI-enhanced analytics
Derwent IP Database — Global patent and intellectual property intelligence
Scopus — Abstract and citation database for research
Google Scholar — Free academic search engine
Recent Developments
(February 2026) Clarivate beat Q4 2025 earnings expectations and issued stronger-than-expected 2026 guidance with 29.9% stock surge
(February 2026) Full redemption of remaining $100 million senior secured notes and $225 million share repurchase program in 2025
(February 2026) Initiated active sale process for Life Sciences & Healthcare segment with Morgan Stanley as advisor
(January 2026) AI-integrated product launches to enhance research and decision-making capabilities
Open the full interactive Clarivate Plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.